Skip to main content
Top
Published in: Annals of Hematology 12/2019

01-12-2019 | Magnetic Resonance Imaging | Original Article

Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis

Authors: Philipp Riffel, Mohamad Jawhar, Kristina Gawlik, Juliana Schwaab, Henrik J. Michaely, Georgia Metzgeroth, Wolf-Karsten Hofmann, Stefan O. Schoenberg, Andreas Reiter

Published in: Annals of Hematology | Issue 12/2019

Login to get access

Abstract

Systemic mastocytosis (SM) is broadly subcategorized according to mast cell (MC) burden and organ involvement into indolent (ISM), smoldering (SSM), and advanced SM (AdvSM). However, the pattern and extent of bone involvement remains controversial. In this institutional review board (IRB)-approved study, 115 patients with different forms of SM (ISM (n = 37, 32%), SSM (n = 9, 8%), and AdvSM (n = 69, 60%)) underwent a whole-body magnetic resonance imaging including sagittal and coronal T1 and turbo inversion recovery magnitude (TIRM) sequences of the spine. The evaluation included the pattern and extent of pathologic bone marrow (BM) signals in the spine and extremities, osteolytic lesions, and vertebral fractures. A pathologic BM pattern was observed in 4/37 (11%), 8/9 (89%), and 66/69 (96%); affection of the appendicular skeleton in 3/37 (8%), 8/9 (89%), and 67/69 (97%); and vertebral fractures in 7/37 (19%), 0/9, and 13/69 (19%) patients with ISM, SSM, and AdvSM, respectively. In AdvSM, pathologic BM pattern included activated (62%), diffuse sclerotic (25%), and small-spotted BM (9%), respectively. Only activated/sclerotic BM was associated with significantly higher MC burden, organ damage, and inferior median survival (2.9 years, p = 0.04). Vertebral fractures resembled classical multi-segmental osteoporotic fractures in ISM but not in AdvSM in which they were only found in activated/sclerotic BM. Only one patient with AdvSM had a focal osteolytic lesion in the femur. Activated/sclerotic BM changes of the spine and affection of the appendicular skeleton are indicative for SSM or AdvSM. Osteolytic lesions, which are very rare, and osteoporotic fractures are ineligible for the diagnosis of AdvSM.
Appendix
Available only for authorised users
Literature
2.
go back to reference Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, Bennett JM, Metcalfe DD (2003) Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122:695–717CrossRef Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, Bennett JM, Metcalfe DD (2003) Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122:695–717CrossRef
3.
go back to reference Horny HP, Parwaresch MR, Lennert K (1985) Bone marrow findings in systemic mastocytosis. Hum Pathol 16:808–814CrossRef Horny HP, Parwaresch MR, Lennert K (1985) Bone marrow findings in systemic mastocytosis. Hum Pathol 16:808–814CrossRef
4.
go back to reference Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRefPubMed Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRefPubMed
5.
go back to reference Valent P, Akin C, Metcalfe DD (2017) Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 129:1420–1427CrossRefPubMed Valent P, Akin C, Metcalfe DD (2017) Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 129:1420–1427CrossRefPubMed
7.
go back to reference Pardanani A (2016) Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. Am J Hematol 91:1146–1159CrossRef Pardanani A (2016) Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. Am J Hematol 91:1146–1159CrossRef
8.
go back to reference Jawhar M, Schwaab J, Meggendorfer M, Naumann N, Horny HP, Sotlar K, Haferlach T, Schmitt K, Fabarius A, Valent P, Hofmann WK, Cross NCP, Metzgeroth G, Reiter A (2017) The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica 102:1035–1043CrossRefPubMed Jawhar M, Schwaab J, Meggendorfer M, Naumann N, Horny HP, Sotlar K, Haferlach T, Schmitt K, Fabarius A, Valent P, Hofmann WK, Cross NCP, Metzgeroth G, Reiter A (2017) The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica 102:1035–1043CrossRefPubMed
9.
go back to reference Jawhar M, Schwaab J, Naumann N, Horny HP, Sotlar K, Haferlach T, Metzgeroth G, Fabarius A, Valent P, Hofmann WK, Cross NCP, Meggendorfer M, Reiter A (2017) Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood 130:137–145CrossRef Jawhar M, Schwaab J, Naumann N, Horny HP, Sotlar K, Haferlach T, Metzgeroth G, Fabarius A, Valent P, Hofmann WK, Cross NCP, Meggendorfer M, Reiter A (2017) Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood 130:137–145CrossRef
10.
go back to reference Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, Horny HP, Metzgeroth G, Kluger S, Naumann N, Haferlach C, Haferlach T, Valent P, Hofmann WK, Fabarius A, Cross NC, Reiter A (2016) Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia 30:136–143CrossRef Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, Horny HP, Metzgeroth G, Kluger S, Naumann N, Haferlach C, Haferlach T, Valent P, Hofmann WK, Fabarius A, Cross NC, Reiter A (2016) Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia 30:136–143CrossRef
11.
go back to reference Jawhar M, Schwaab J, Hausmann D, Clemens J, Naumann N, Henzler T, Horny HP, Sotlar K, Schoenberg SO, Cross NC, Fabarius A, Hofmann WK, Valent P, Metzgeroth G, Reiter A (2016) Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia 30:2342–2350CrossRef Jawhar M, Schwaab J, Hausmann D, Clemens J, Naumann N, Henzler T, Horny HP, Sotlar K, Schoenberg SO, Cross NC, Fabarius A, Hofmann WK, Valent P, Metzgeroth G, Reiter A (2016) Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia 30:2342–2350CrossRef
12.
go back to reference Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NC, Reiter A (2013) Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 122:2460–2466CrossRef Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NC, Reiter A (2013) Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 122:2460–2466CrossRef
13.
go back to reference Metzgeroth G, Dinter D, Erben P, La Rosee P, Hehlmann R, Hastka J (2007) Systemic mastocytosis simulating osseous metastatic disease. Br J Haematol 136:1CrossRef Metzgeroth G, Dinter D, Erben P, La Rosee P, Hehlmann R, Hastka J (2007) Systemic mastocytosis simulating osseous metastatic disease. Br J Haematol 136:1CrossRef
14.
go back to reference Deb A, Tefferi A (2003) Images in clinical medicine. Systemic mastocytosis N Engl J Med 349:e7CrossRef Deb A, Tefferi A (2003) Images in clinical medicine. Systemic mastocytosis N Engl J Med 349:e7CrossRef
15.
go back to reference Myers B, Grimley C, Jones SG, Clark D, Kerslake R (2003) Skin, bone marrow and magnetic resonance imaging appearances in systemic mastocytosis. Br J Haematol 122:876CrossRef Myers B, Grimley C, Jones SG, Clark D, Kerslake R (2003) Skin, bone marrow and magnetic resonance imaging appearances in systemic mastocytosis. Br J Haematol 122:876CrossRef
16.
go back to reference Epelboym Y, Keraliya AR, Tirumani SH, Hornick JL, Ramaiya NH, Shinagare AB (2017) Differences in the imaging features and distribution of non-indolent and indolent mastocytosis: a single institution experience of 29 patients. Clin Imaging 44:111–116CrossRef Epelboym Y, Keraliya AR, Tirumani SH, Hornick JL, Ramaiya NH, Shinagare AB (2017) Differences in the imaging features and distribution of non-indolent and indolent mastocytosis: a single institution experience of 29 patients. Clin Imaging 44:111–116CrossRef
17.
go back to reference Huang TY, Yam LT, Li CY (1987) Radiological features of systemic mast-cell disease. Br J Radiol 60:765–770CrossRef Huang TY, Yam LT, Li CY (1987) Radiological features of systemic mast-cell disease. Br J Radiol 60:765–770CrossRef
18.
go back to reference Avila NA, Ling A, Metcalfe DD, Worobec AS (1998) Mastocytosis: magnetic resonance imaging patterns of marrow disease. Skelet Radiol 27:119–126CrossRef Avila NA, Ling A, Metcalfe DD, Worobec AS (1998) Mastocytosis: magnetic resonance imaging patterns of marrow disease. Skelet Radiol 27:119–126CrossRef
19.
go back to reference Roca M, Mota J, Giraldo P, Garcia Erce JA (1999) Systemic mastocytosis: MRI of bone marrow involvement. Eur Radiol 9:1094–1097CrossRef Roca M, Mota J, Giraldo P, Garcia Erce JA (1999) Systemic mastocytosis: MRI of bone marrow involvement. Eur Radiol 9:1094–1097CrossRef
20.
go back to reference Siegel S, Sadler MA, Yook C, Chang V, Miller J (1999) Systemic mastocytosis with involvement of the pelvis: a radiographic and clinicopathologic study--a case report. Clin Imaging 23:245–248CrossRef Siegel S, Sadler MA, Yook C, Chang V, Miller J (1999) Systemic mastocytosis with involvement of the pelvis: a radiographic and clinicopathologic study--a case report. Clin Imaging 23:245–248CrossRef
21.
go back to reference Di Leo C, Lodi A, Pozzato C et al (2003) Systemic mastocytosis: bone marrow involvement assessed by Tc-99m MDP scintigraphy and magnetic resonance imaging. Haematologica 88:Ecr26 Di Leo C, Lodi A, Pozzato C et al (2003) Systemic mastocytosis: bone marrow involvement assessed by Tc-99m MDP scintigraphy and magnetic resonance imaging. Haematologica 88:Ecr26
22.
go back to reference Sperr WR, Valent P (2012) Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol 5:261–274CrossRef Sperr WR, Valent P (2012) Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol 5:261–274CrossRef
23.
go back to reference Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG (1988) Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 67:345–368CrossRef Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG (1988) Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 67:345–368CrossRef
24.
go back to reference Armingaud P, Zerkak D, Lespessailles E et al (2002) Bone evaluation in ten adults with cutaneous mastocytosis. Ann Dermatol Venereol 129:170–172 Armingaud P, Zerkak D, Lespessailles E et al (2002) Bone evaluation in ten adults with cutaneous mastocytosis. Ann Dermatol Venereol 129:170–172
25.
go back to reference Grieser T, Minne HW (1997) Systemic mastocytosis and skeletal lesions. Lancet 350:1103–1104CrossRef Grieser T, Minne HW (1997) Systemic mastocytosis and skeletal lesions. Lancet 350:1103–1104CrossRef
26.
go back to reference Brumsen C, Hamdy NA, Papapoulos SE (2002) Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 17:567–569CrossRef Brumsen C, Hamdy NA, Papapoulos SE (2002) Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 17:567–569CrossRef
27.
go back to reference Lim AY, Ostor AJ, Love S, Crisp AJ (2005) Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 64:965–966CrossRefPubMed Lim AY, Ostor AJ, Love S, Crisp AJ (2005) Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 64:965–966CrossRefPubMed
28.
go back to reference Jawhar M, Schwaab J, Horny HP, Sotlar K, Naumann N, Fabarius A, Valent P, Cross NC, Hofmann WK, Metzgeroth G, Reiter A (2016) Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Eur J Clin Investig 46:392–397CrossRef Jawhar M, Schwaab J, Horny HP, Sotlar K, Naumann N, Fabarius A, Valent P, Cross NC, Hofmann WK, Metzgeroth G, Reiter A (2016) Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Eur J Clin Investig 46:392–397CrossRef
29.
go back to reference Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F, Dubreuil P, Arock M, Roux C, Launay JM, Fraitag S, Canioni D, Billemont B, Suarez F, Lanternier F, Lortholary O, Hermine O, Francès C (2010) Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 69:1838–1841CrossRef Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F, Dubreuil P, Arock M, Roux C, Launay JM, Fraitag S, Canioni D, Billemont B, Suarez F, Lanternier F, Lortholary O, Hermine O, Francès C (2010) Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 69:1838–1841CrossRef
30.
go back to reference Kluin-Nelemans HC, Jansen JH, Breukelman H et al (1992) Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 326:619–623CrossRef Kluin-Nelemans HC, Jansen JH, Breukelman H et al (1992) Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 326:619–623CrossRef
31.
go back to reference Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, Vecchiato D, Bonifacio M, Viapiana O, Gatti D, Senna G, Riccio A, Passalacqua G, Pizzolo G, Adami S (2011) Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 49:880–885CrossRef Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, Vecchiato D, Bonifacio M, Viapiana O, Gatti D, Senna G, Riccio A, Passalacqua G, Pizzolo G, Adami S (2011) Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 49:880–885CrossRef
32.
go back to reference Manara M, Varenna M, Cantoni S, Parafioriti A, Gallazzi MB, Sinigaglia L (2010) Osteoporosis with vertebral fractures in young males, due to bone marrow mastocytosis: a report of two cases. Clin Exp Rheumatol 28:97–100 Manara M, Varenna M, Cantoni S, Parafioriti A, Gallazzi MB, Sinigaglia L (2010) Osteoporosis with vertebral fractures in young males, due to bone marrow mastocytosis: a report of two cases. Clin Exp Rheumatol 28:97–100
33.
go back to reference Theoharides TC, Boucher W, Spear K (2002) Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 128:344–350CrossRef Theoharides TC, Boucher W, Spear K (2002) Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 128:344–350CrossRef
34.
go back to reference Brockow K, Akin C, Huber M, Metcalfe DD (2005) IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 115:216–223CrossRef Brockow K, Akin C, Huber M, Metcalfe DD (2005) IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 115:216–223CrossRef
35.
go back to reference Kanzaki S, Takahashi T, Kanno T, Ariyoshi W, Shinmyouzu K, Tujisawa T, Nishihara T (2008) Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor. J Cell Physiol 216:844–850CrossRef Kanzaki S, Takahashi T, Kanno T, Ariyoshi W, Shinmyouzu K, Tujisawa T, Nishihara T (2008) Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor. J Cell Physiol 216:844–850CrossRef
36.
go back to reference Johansson C, Roupe G, Lindstedt G, Mellstrom D (1996) Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 25:1–7CrossRef Johansson C, Roupe G, Lindstedt G, Mellstrom D (1996) Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 25:1–7CrossRef
Metadata
Title
Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis
Authors
Philipp Riffel
Mohamad Jawhar
Kristina Gawlik
Juliana Schwaab
Henrik J. Michaely
Georgia Metzgeroth
Wolf-Karsten Hofmann
Stefan O. Schoenberg
Andreas Reiter
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 12/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-019-03826-4

Other articles of this Issue 12/2019

Annals of Hematology 12/2019 Go to the issue